This stock, IMO, is overpriced, but it might just keep going! They have one FDA Approved drug ([ARCALYST® (rilonacept)]. IMO, a very exciting area is that for LDL cholesterol control. This is through PCSK9. I attached a recent PCSK9 review article. Quote: REGENERON recently communicated an interim efficacy analysis of a dose-escalating, randomized, double-blind, placebo-controlled, Phase 1 trial in healthy volunteers with its monoclonal antibody REG727. Both intravenous and subcutaneous routes of administration are being tested. A significant decrease of LDL-C, lasting over a month after a single dose, was reported with a maximum 60% decrease of mean LDL-C (Investor Day event, Regeneron Pharmaceuticals, Inc. - Regeneron Provides Initial Data on Two Antibody Product Candidates ). PCSK9 Blockers: The Next Big Thing? Insight: Next big drug against cholesterol takes shape | Reuters Separate paths lead to promising cholesterol drug Separate paths lead to promising cholesterol drug | Reuters Waiting, Watching, . . . Regeneron Pharmaceuticals, Inc. (Public, NASDAQ:REGN) REGENERON IR: REGENERON > Investor Relations GF: Regeneron Pharmaceuticals, Inc.: NASDAQ:REGN quotes & news - Google Finance YF: REGN: Summary for Regeneron Pharmaceuticals, Inc.- Yahoo! Finance SA: Regeneron Pharmaceuticals, Inc. (REGN) Stock - Seeking Alpha SEC: 0000872589 (see all company filings) ARCALYST® (rilonacept) - For the Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) REGENERON > Marketed Products > ARCALYST<sup>?</sup> In February 2008, the U.S. Food and Drug Administration (FDA) approved ARCALYST Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Regeneron has 11 investigational product candidates progressing through all stages of human clinical trials for a diverse set of serious diseases including cancer, eye diseases, inflammatory diseases, pain, cardiovascular/metabolic diseases, and allergic conditions. The Company draws on strong internal capabilities and its collaborations with the sanofi-aventis Group and Bayer HealthCare to manage these significant clinical efforts. REGENERON > Clinical Pipeline Regeneron and sanofi-aventis are collaborating on the discovery, development, and commercialization of fully human monoclonal antibodies generated using our Velocimmune® technology. REGENERON > Clinical Pipeline > VelocImmune Antibodies These antibodies are in clinical development: REGN727 (PCSK9 antibody) - An antibody to PCSK9, a novel target for LDL cholesterol reduction in patients with hyperlipidemia. REGN88 (IL-6R antibody) - An antibody to the interleukin-6 receptor in development for the treatment of rheumatoid arthritis and ankylosing spondylitis. REGN421 (Dll4 antibody) - An antibody to delta-like ligand-4 (Dll4) in development to disrupt angiogenesis in patients with cancer. REGN668 (IL4R antibody) - An antibody to the Interleukin 4 receptor that modulates the effects of IL4 and IL13 in certain allergic and immune conditions. REGN475 (NGF antibody) - An antibody to nerve growth factor (NGF), a novel target for the treatment of pain. Currently on clinical hold. REGN910 - An antibody to angiopoietin-2 (ANG2), a novel angiogenesis target for inhibiting tumor growth in oncology. REGN846 - Target undisclosed. REGN728 - Target undisclosed.